Aurobindo Pharma gets Health Canada NOC for Bevqolva

What Aurobindo Pharma disclosed

Aurobindo Pharma told stock exchanges that its wholly owned subsidiary, CuraTeQ Biologics, has received a Notice of Compliance (NOC) from Health Canada for Bevqolva, its bevacizumab biosimilar. The approval was issued by Health Canada’s Biologics and Radiopharmaceutical Drugs Directorate (BRDD). In its regulatory filing, Aurobindo Pharma said the NOC follows a successful review and grants formal marketing authorisation. The company added that the notice confirms the product meets regulatory standards for safety, efficacy, and quality. It also stated that these standards are comparable to the reference biologic drug under the Food and Drug Regulations.

The regulator and the approval route

The clearance came from Health Canada’s BRDD, which evaluates biologics and radiopharmaceutical drugs. Aurobindo Pharma described the NOC as the outcome of a successful review. In practical terms, the NOC is Health Canada’s formal confirmation that a product meets the country’s regulatory requirements. The company emphasised the three pillars that underpin the decision: safety, efficacy, and quality. It also underlined the concept of comparability, stating that the biosimilar is assessed against the reference biologic drug.

What Bevqolva is

Bevqolva is a biosimilar of bevacizumab. The article notes that bevacizumab is a biological medication used to treat several types of cancer by inhibiting the growth of blood vessels that supply tumours. Bevqolva is positioned as a biosimilar to the blockbuster drug Avastin (bevacizumab), as referenced in the provided material. The Health Canada NOC therefore places CuraTeQ’s product into a regulated market with an approval that allows marketing authorisation, subject to local rules and product labelling.

Indications mentioned for cancer treatment

Aurobindo Pharma said Bevqolva is indicated in the treatment of different types of cancer. The provided material also states that the biosimilar is approved for six indications, including colorectal and lung cancers. Separately, the text lists multiple cancers for which bevacizumab is used, including metastatic colorectal cancer and recurrent or metastatic non-squamous non-small cell lung cancer. It further mentions advanced and/or metastatic renal cell carcinoma, cervical cancer, and epithelial ovarian, fallopian tube, and primary peritoneal cancer. Taken together, the approvals are framed around use across a range of solid tumours, with six indications specifically highlighted.

Dosage form and presentation details

Beyond the Canadian decision, the provided content includes product presentation information for Bevqolva. It says Bevqolva is administered only via intravenous infusion. It will be available as a 25 mg/mL concentrate. The pack sizes listed are 4 mL (100 mg) and 16 mL (400 mg) single-use vials. These details matter for hospital procurement and oncology infusion settings, where vial size and concentration influence dosing logistics, inventory planning, and wastage management.

How the event unfolded

The announcement came via a regulatory filing and exchange communication by Aurobindo Pharma. The company described the NOC as a compliance notice from Health Canada for Bevqolva and attributed it to BRDD. It repeated the explanation of what an NOC signifies, focusing on formal marketing authorisation and the confirmation of safety, efficacy, and quality standards. The filing also linked the review process to Canada’s Food and Drug Regulations and the requirement that the biosimilar be comparable to the reference biologic. The disclosures did not provide commercial launch dates, pricing, or sales targets.

Why regulated-market approvals matter for biosimilars

The material frames the Health Canada nod as an expansion into high-value regulated markets. It also calls the approval a boost to Aurobindo Pharma’s oncology pipeline and a milestone in the company’s global biosimilar strategy. While the filing does not quantify market size or revenue opportunity, it does connect approval to “potential new market opportunities” and portfolio expansion. In biosimilars, approvals in markets like Canada typically require detailed evidence packages and comparability demonstrations, and the NOC language in the filing reflects that regulatory emphasis.

Other regulatory progress mentioned: UK MHRA authorisation

The provided content also states that CuraTeQ Biologics received marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Bevqolva, described as a biosimilar version of bevacizumab. One section identifies CuraTeQ Biologics s.r.o. as a step-down subsidiary of Aurobindo Pharma Limited in the UK context. The MHRA authorisation is presented as a separate regulatory outcome from the Health Canada NOC. Together, these points indicate progress across multiple regulated jurisdictions for the same biosimilar brand.

Key facts at a glance

Market impact and what investors can take away

The immediate market takeaway from the filing is that Aurobindo Pharma’s biosimilars platform, via CuraTeQ Biologics, has secured a Canadian marketing authorisation for an oncology biosimilar. The company’s statement focuses on regulatory validation of safety, efficacy, and quality, which is central to biosimilar acceptance in regulated markets. The approval also supports the broader theme highlighted in the material: expanding the biosimilars portfolio and accessing new markets. However, the announcement does not include a commercial timeline, financial guidance, or any quantified demand outlook. As a result, any assessment of revenue contribution would depend on future disclosures, launch execution, and competitive dynamics that are not detailed in the text.

Conclusion

CuraTeQ Biologics’ Health Canada NOC for Bevqolva gives Aurobindo Pharma a fresh regulated-market approval for its bevacizumab biosimilar used across multiple cancer indications. The filing positions the NOC as confirmation of safety, efficacy, and quality comparability to the reference biologic under Canadian regulations. The material also notes separate UK MHRA marketing authorisation and provides details on the intravenous formulation and vial sizes. The next concrete updates to watch will be any company communication on launch timing and market rollout, which were not included in the current disclosure.